Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors

Bone Marrow Transplantation

Volumn 45, Issue 4, 2010, Pages 786-788

  Brissot, E ^a   Chevallier, P ^a   Guillaume, T ^a   Delaunay, J ^a   Ayari, S ^a   Dubruille, V ^a   Le Gouill, S ^a,b   Mahe, B ^a   Gastinne, T ^a   Blin, N ^a   Saulquin, B ^a   Moreau, P ^a,b   Harousseau, J L ^a,b,c   Mohty, M ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG TOLERABILITY; ENGRAFTMENT; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LETTER; MALE; MONOTHERAPY; MULTIPLE ORGAN FAILURE; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT;

EID: 77950624881     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.218     Document Type: Letter

References (10)

1. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021-2030.
2. Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M, Kirsten D et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61-65. (Pubitemid 28330537)
3. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470-476. (Pubitemid 36841962)
4. Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L et al. Infectious complications following allogeneic HLAidentical sibling transplantation with antithymocyte globulinbased reduced intensity preparative regimen. Leukemia 2003; 17: 2168-2177. (Pubitemid 37428382)
5. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L et al. Chronic graft versus host disease after allogeneic blood stem cell transplantation: long term results of a randomized study. Blood 2002; 100: 3128-3134.
6. Jacobson P, El-Massah SF, Rogosheske J, Kerr A, Long-Boyle J, Defor T et al. Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44: 113-120.
7. Mohty M, de Lavallade H, Faucher C, Bilger K, Vey N, Stoppa AM et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 527-530. (Pubitemid 39264044)
8. Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005; 106: 4381-4388.
9. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
10. Cahu X, Mohty M, Faucher C, Chevalier P, Vey N, El-Cheikh J et al. Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens. Bone Marrow Transplant 2008; 42: 689-691.